Adaptive Biotechnologies Corp
ADPT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001478320
In the last 90 days, Adaptive Biotechnologies Corp insiders filed 0 open-market purchases and 18 sales; 305 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; superinvestors Viking Global Investors and ARK Invest hold it.
Key figures
- Market capClose on Nov 11, 2026
- $4.85B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $32.4M in total
- 18
- 13F holdersQ2 2026, +6 vs. previous quarter
- 305
- 13F valueReported value at the end of Q2 2026
- $3.34B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $277.0M
- +54.8% year over year
- Net income, FY2025
- -$59.5M
- No comparable prior period
- Free cash flow, FY2025
- -$48.9M
- No comparable prior period
- Revenue, Q3 FY2026
- $83.9M
- −10.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $59.5M (21.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 11.5M
- Shares sold short
- Change
- −513.2K
- −4.3% vs. previous
- Days to cover
- 6.07
- At average daily volume
Superinvestors holding ADPT, Q2 2026
Go to the superinvestors tab2 superinvestors report holding Adaptive Biotechnologies Corp on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.8%
Adaptive Biotechnologies Corp's share of the portfolio
- Shares
- 29,993,708
- Value
- $643.4M
ARK Invest
Cathie Wood
0.3%
Adaptive Biotechnologies Corp's share of the portfolio
- Shares
- 2,090,306
- Value
- $44.8M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Adaptive Biotechnologies Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 (view filing)7:26 PM ET | Nov 9-10 | 1 day | Rubinstein JuliePresident and COO | SSale | −23.8K | $29.82 | −$708.6K | −5.9%377.8K after | 5 lots10b5-1 |
| Nov 6, 2026 (view filing)7:24 PM ET | Nov 4-6 | 2 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $26.78 | −$954.4K | −8.6%377.8K after | 7 lots10b5-1 |
| Nov 3, 2026 (view filing)7:51 PM ET | Oct 30-Nov 3 | 4 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $26.06 | −$928.9K | −8.6%377.8K after | 5 lots10b5-1 |
| Oct 29, 2026 (view filing)7:52 PM ET | Oct 27-29 | 2 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $28.00 | −$998.1K | −8.6%377.8K after | 5 lots10b5-1 |
| Oct 26, 2026 (view filing)6:52 PM ET | Oct 22-26 | 4 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $25.18 | −$897.5K | −8.6%377.8K after | 6 lots10b5-1 |
| Oct 21, 2026 (view filing)6:36 PM ET | Oct 19-21 | 2 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $24.66 | −$879.1K | −8.6%377.8K after | 5 lots10b5-1 |
| Oct 16, 2026 (view filing)7:21 PM ET | Oct 14-16 | 2 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $25.18 | −$897.4K | −8.6%377.8K after | 5 lots10b5-1 |
| Oct 13, 2026 (view filing)7:05 PM ET | Oct 9-13 | 4 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $25.81 | −$919.9K | −8.6%377.8K after | 4 lots10b5-1 |
| Oct 8, 2026 (view filing)6:54 PM ET | Oct 6-8 | 2 days | Rubinstein JuliePresident and COO | SSale | −35.6K | $26.60 | −$948.2K | −8.6%377.8K after | 6 lots10b5-1 |
| Oct 8, 2026 (view filing)6:52 PM ET | Oct 6 | 2 days | Bobulsky SusanChief Commercial Officer, MRD | SSale | −6.44K | $30.00 | −$193.3K | −1.6%389.4K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 305 holdersThe largest institutional positions in Adaptive Biotechnologies Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 29,993,708 | $643.4M | 1.83% | 00.0% | Unchanged |
| BlackRock, Inc. | 15,139,159 | $324.7M | 0.00% | +1,836,134+13.8% | Added |
| Vanguard Capital Management LLC | 6,403,587 | $137.4M | 0.00% | +309,443+5.1% | Added |
| Wellington Management Group LLP | 5,911,366 | $126.8M | 0.02% | +2,053,944+53.2% | Added |
| Vanguard Portfolio Management LLC | 5,476,231 | $117.5M | 0.01% | +984,757+21.9% | Added |
| D. E. Shaw & Co., Inc. | 4,625,859 | $99.2M | 0.06% | +2,660,249+135.3% | Added |
| Westfield Capital Management Co LP | 4,267,645 | $91.5M | 0.30% | −1,169,073−21.5% | Reduced |
| Geode Capital Management, LLC | 3,641,837 | $78.1M | 0.00% | +5,783+0.2% | Added |
| State Street Corp | 3,458,388 | $74.2M | 0.00% | +231,143+7.2% | Added |
| Invesco Ltd. | 3,094,011 | $66.4M | 0.01% | −1,356,055−30.5% | Reduced |
Holders of 5% or more of ADPT
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Adaptive Biotechnologies Corp.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Viking Global Investors LPSuperinvestorViking Global Investors | 13G/A | 18.80%30.0M shares | – | Feb 16, 20214 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.90%12.0M shares | +1.20 ppfrom 6.70% | Apr 17, 20252 filings | Jan 21, 2026 | SEC |